Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study

[1]  J. Wedzicha,et al.  Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. , 2022, The Lancet. Respiratory medicine.

[2]  K. Rabe,et al.  The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. , 2022, The Lancet. Respiratory medicine.

[3]  H. Tillmann,et al.  A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma , 2022, Advances in Therapy.

[4]  C. Raherison-Semjen,et al.  Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study , 2021, Airway pharmacology and treatment.

[5]  Li He,et al.  FEF25-75% is a more sensitive measure reflecting airway dysfunction in patients with asthma: a comparison study using FEF25-75% and FEV1. , 2021, The journal of allergy and clinical immunology. In practice.

[6]  H. Sagara,et al.  Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population , 2021, BMJ Open Respiratory Research.

[7]  H. J. Kim,et al.  FEF25-75% Values in Patients with Normal Lung Function Can Predict the Development of Chronic Obstructive Pulmonary Disease , 2020, International journal of chronic obstructive pulmonary disease.

[8]  O. Heudi,et al.  Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. , 2020, Pulmonary pharmacology & therapeutics.

[9]  Y. Gon,et al.  Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[10]  H. Kerstjens,et al.  Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[11]  A. Gézsi,et al.  Prevalence and characterization of severe asthma in Hungary , 2020, Scientific Reports.

[12]  J. Virchow,et al.  Extrafine triple therapy in patients with asthma and persistent airflow limitation , 2020, European Respiratory Journal.

[13]  M. Dastoorpoor,et al.  Forced Expiratory Flow at 25–75% as a Marker for Airway Hyper Responsiveness in Adult Patients with Asthma-like Symptoms , 2018, Tanaffos.

[14]  S. Salvi,et al.  Peak flow meter with a questionnaire and mini-spirometer to help detect asthma and COPD in real-life clinical practice: a cross-sectional study , 2017, npj Primary Care Respiratory Medicine.

[15]  S. Guerra,et al.  Asthma, airflow limitation and mortality risk in the general population , 2015, European Respiratory Journal.

[16]  F. Muñoz-López,et al.  The interest of FEF(25-75) in evaluating bronchial hyperresponsiveness with the methacholine test. , 2012, Allergologia et immunopathologia.

[17]  Michael Engel,et al.  Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.

[18]  Thomas M. Smith,et al.  Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects , 2012 .

[19]  W. Phipatanakul,et al.  The Utility of Forced Expiratory Flow between 25% and 75% of Vital Capacity in Predicting Childhood Asthma Morbidity and Severity , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[20]  A. ten Brinke.  Risk factors associated with irreversible airflow limitation in asthma , 2008, Current opinion in allergy and clinical immunology.

[21]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[22]  A. Zwinderman,et al.  Factors associated with persistent airflow limitation in severe asthma. , 2001, American journal of respiratory and critical care medicine.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[24]  A. Woolcock.  Effect of drugs on small airways. , 1998, American journal of respiratory and critical care medicine.

[25]  S. Spector,et al.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. , 2000, American journal of respiratory and critical care medicine.